ADVERTISEMENT
Conference Coverage
Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
07/22/2024
Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma.
Source:
Ascierto P. Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #LBA9513
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement